Phospho-LATS1 (Thr1079) Polyklonaler Antikörper

Phospho-LATS1 (Thr1079) Polyklonal Antikörper für WB, ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human

Anwendung

WB, IHC, ELISA

Konjugation

Unkonjugiert

Publikationen(11)

Kat-Nr. : 28998-1-AP

Synonyme

h warts, LATS1, Phospho-LATS1 (Thr1079), WARTS, WARTS protein kinase, wts

---

• 

  WB analysis using 28998-1-AP

  Non-treated and Calyculin A treated HeLa cells were subjected to SDS PAGE followed by western blot with 28998-1-AP (Phospho-LATS1 (Thr1079) antibody) at dilution of 1:20000 incubated at room temperature for 1.5 hours.

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in WB: Mit Calyculin A behandelte HeLa-Zellen

Empfohlene Verdünnung

• Western Blot (WB): WB : 1:5000-1:50000

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Veröffentlichte Anwendungen

• WB: See 10 publications below
• IHC: See 1 publications below

Produktinformation

28998-1-AP bindet in WB, IHC, ELISA Phospho-LATS1 (Thr1079) und zeigt Reaktivität mit human

• Getestete Reaktivität: human
• In Publikationen genannte Reaktivität: human
• Wirt / Isotyp: Kaninchen / IgG
• Klonalität: Polyklonal
• Typ: Antikörper
• Immunogen: Peptid
• Vollständiger Name: LATS, large tumor suppressor, homolog 1 (Drosophila)
• Berechnetes Molekulargewicht: 15 kDa, 127 kDa
• Beobachtetes Molekulargewicht: 140-150 kDa
• GenBank-Zugangsnummer: BC015665
• Gene symbol: LATS1
• Gene ID (NCBI): 9113
• Konjugation: Unkonjugiert
• Form: Liquid
• Reinigungsmethode: Antigen-Affinitätsreinigung
• Lagerungspuffer: PBS with 0.02% sodium azide and 50% glycerol
• Lagerungsbedingungen: Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

The large tumour suppressor 1 (LATS1) acting as a tumour suppressor is a serine/threonine kinase of the AGC kinase family and is found to be down-regulated in various types of human cancers. Recently, LATS1 has been identified as a central player of the emerging tumour suppressive Hippo signaling pathway. In this pathway, the MST1/2 kinase phosphorylates activates LATS1/2 which, together with its co-factor MOB1, subsequently phosphorylates and inhibits the YAP transcriptional factor by preventing them from translocating to the nucleus. The antibody also detects the phosphorylated at Thr1041 of the LATS2. (PMID: 32460168, PMID: 30219064,PMID: 31792377)

Publikationen

Species	Application	Title
human	WB	Int J Biol Sci; S100 Calcium Binding Protein A16 Promotes Cell Proliferation by triggering LATS1 ubiquitin degradation mediated by CUL4A ligase to inhibit Hippo pathway in Glioma development; Authors - Yifang Hu
human	WB	Cell Mol Biol Lett; KIAA1429-mediated m6A modification of CHST11 promotes progression of diffuse large B-cell lymphoma by regulating Hippo-YAP pathway; Authors - Xiaomin Chen
		J Transl Med; Modulation of SRC by SNTB1 activates the Hippo-YAP pathway during colon adenocarcinoma metastasis; Authors - Zhengyan Chang
human	WB,IHC	IUBMB Life; Upstream transcription factor 1 suppresses laryngeal squamous cell carcinoma progression through transcriptional activation of junctional adhesion molecule 3; Authors - Yue Jia
human	WB	Biochem Biophys Res Commun; IGF2BP1 enhances the stability of SIK2 mRNA through m6A modification to promote non-small cell lung cancer progression; Authors - Yan Xu
human	WB	Exp Eye Res; Targeting mechanics-induced trabecular meshwork dysfunction through YAP-TGFβ Ameliorates high myopia-induced ocular hypertension; Authors - Qianwen Bu